Thompson Davis & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Thompson Davis & Co’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-269	Closed	-$14K	–	873
2017 Q3	$14K	Hold	269	–	–	0.02%	587
2017 Q2	$14K	Hold	269	–	–	0.02%	566
2017 Q1	$11K	Hold	269	–	–	0.02%	667
2016 Q4	$13K	Buy	269 +129	+92%	+$5.1K	0.02%	627
2016 Q3	$5K	Hold	140	–	–	0.01%	831
2016 Q2	$3K	Sell	140 -355	-72%	-$11.5K	﹤0.01%	884
2016 Q1	$20K	Buy	495 +74	+18%	+$3.01K	0.03%	461
2015 Q4	$26K	Sell	421 -19	-4%	-$1.02K	0.04%	387
2015 Q3	$18K	Sell	440 -10	-2%	-$518	0.03%	496
2015 Q2	$26K	Hold	450	–	–	0.03%	472
2015 Q1	$29K	Sell	450 -23	-5%	-$1.56K	0.03%	431
2014 Q4	$29K	Buy	473 +14	+3%	+$691	0.03%	409
2014 Q3	$18K	Buy	459 +209	+84%	+$7.41K	0.02%	499
2014 Q2	$9K	Buy	+250	New	+$7.87K	0.01%	497

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Thompson Davis & Co's IONS Position: Q4 2017 in Review

Thompson Davis & Co sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 269 shares — an estimated $14K sold.

Thompson Davis & Co first reported a position in IONS in Q2 2014 and held it in 14 quarters. The position peaked at $29K in Q1 2015. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

Thompson Davis & Co reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Thompson Davis & Co sold 269 Ionis Pharmaceuticals shares in Q4 2017, an estimated $14K.
Thompson Davis & Co first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 14 quarters.
Thompson Davis & Co's Ionis Pharmaceuticals position peaked at $29K in Q1 2015.
316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.